2026
conference-abstract
OpenAlex
Jianmin Wu, Jian Zhang, Quchang Ouyang, Yiqun Du et autres
LBA1003 Background: Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive biology and limited treatment options beyond first-line immunotherapy plus chemotherapy. Patients who progress after taxane-containing regimens face poor outcomes and have a high unmet need. Izalontamab brengitecan (iza-bren) …
cn
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Kuikui Jiang, Shusen Wang, Qingyuan Zhang, Jing Sun et autres
1076 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy are standard first-line treatment for HR-positive/HER2-negative (HR + /HER2 - ) metastatic breast cancer (MBC). However, patients with brain metastases have poor prognosis and limited treatment options due to inadequate blood-brain barrier …
cn
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Yeon Hee Park, Sara M. Tolaney, Cristina Saura Manich, Z F Jiang et autres
1021 Background: In DESTINY-Breast09 (NCT04784715), first-line (1L) T-DXd + P demonstrated durable responses, a near doubling of complete response (CR) rates, and significantly improved progression-free survival (PFS) vs taxane + trastuzumab + pertuzumab for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC). …
kr, us, es, cn, br, de, jp, tr, mx, it, ca, nl, pl
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Herui Yao, Zhangzhou Huang, Hong Zong, Min Yan et autres
1123 Background: TROP2 and HER3 are frequently overexpressed in most of solid tumors. JSKN016 is a first-in-class bispecific ADC targeting TROP2/HER3, site specifically conjugated to topoisomerase I inhibitor via a cleavable linker (DAR4). Glycan conjugation provides high stability and minimizes off-target toxicity. …
cn
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
He-Rui Yao, Yehui Shi, Yuemei Mo, Yaping Yang et autres
1049 Background: T-Bren is a HER2-directed antibody-drug conjugate (ADC) consisting of an anti-HER2 monoclonal antibody linked to a potent topoisomerase I inhibitor (Ed-04). In phase I study, T-Bren demonstrated encouraging antitumor activity with a manageable safety profile in patients (pts) with HER2-positive …
cn
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Shigehisa Kitano, Matteo Simonelli, Ramón Yarza, Junhua Zhang et autres
1044 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxicities. Beamion BCGC-1 (NCT06324357) is an ongoing Ph Ib/II multicohort trial investigating zongertinib as monotherapy or in combination with other agents in HER2-positive mBC, metastatic colorectal …
jp, it, cn, us, de, at
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Qingyuan Zhang, J. Xu, Z. Tong, X. Wang et autres
Imlu is a next-generation, brain-penetrant, oral SERD. The EMBER-3 trial (NCT04975308) in pts with ER+, HER2- ABC with disease progression on prior endocrine therapy +/- CDK4/6 inhibitor showed significant progression-free survival (PFS) benefit with imlu vs standard therapy (SOC: fulvestrant or exemestane) …
cn, tw, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Lina Zhang, Yi-Xiang Wang, Tao Sun, Li F et autres
Background: SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer. Methods: Patients with histologically or cytologically …
cn
(code pays fourni par la source)
2012
conference-abstract
OpenAlex
Binghe Xu, S-A Im, Y-H Im, Jungsil Ro et autres
Abstract Background: Afatinib is a ErbB Family Blocker that irreversibly blocks signaling from all relevant ErbB Family dimers. Afatinib is being developed in EGFR (ErbB1)-driven (non-small cell lung cancer [NSCLC]/head and neck squamous cell carcinoma) and HER2 (ErbB2)-driven (breast) malignancies, and has …
cn, us, kr, in
(code pays fourni par la source)